Effectiveness of the targeted hepatitis B vaccination program in Greenland

American Journal of Public Health

Volumn 102, Issue 2, 2012, Pages 277-284

  Børresen, Malene L ^a   Koch, Anders ^a   Biggar, Robert J ^a   Ladefoged, Karin ^b   Melbye, Mads ^a   Wohlfahrt, Jan ^a   Krause, Tyra Grove ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Dronning Ingrids Hospital   (Greenland)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; ARTICLE; BLOOD; DISEASE TRANSMISSION; FEMALE; GREENLAND; HEALTH CARE QUALITY; HEPATITIS B; HUMAN; IMMUNOLOGY; INFANT; MOTHER; NEWBORN; PREGNANCY; PREGNANCY COMPLICATION; PREVENTIVE HEALTH SERVICE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS; VERTICAL TRANSMISSION;

ADULT; FEMALE; GREENLAND; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROGRAM EVALUATION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84857340273     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2011.300239     Document Type: Article

References (35)

1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337(24):1733- 1745. (Pubitemid 27527771)
2. Jonas MM. Hepatitis B and pregnancy: an underestimated issue. Liver Int. 2009;29(suppl 1): 133-139.
3. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis. BMJ. 2006;332(7537): 328-336.
4. McGregor A.WHO: World Health Assembly. Lancet. 1992;339(8804):1287.
5. Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ. Economic evaluations of hepatitis B vaccination for developing countries. Expert Rev Vaccines. 2009;8(7):907-920.
6. Expanded Programme on Immunization, Department of Immunization, Vaccines and Biologicals. WHO Vaccine-Preventable Diseases: Monitoring System. 2008 Global Summary. Geneva, Switzerland: World Health Organization; 2008.
7. Langer BC, Frosner GG, von Brunn A. Epidemiological study of viral hepatitis types A, B, C, D and E among Inuits in West Greenland. J Viral Hepat. 1997; 4(5):339-349. (Pubitemid 127733424)
8. Skinhøj P, Hart Hansen JP, Nielsen NH, Mikkelsen F. Occurrence of cirrhosis and primary liver cancer in an Eskimo population hyperendemically infected with hepatitis B virus. Am J Epidemiol. 1978;108(2): 121-125. (Pubitemid 9148065)
9. Skinhøj P. Hepatitis and hepatitis B-antigen in Greenland. II: Occurrence and interrelation of hepatitis B associated surface, core, and "e" antigen-antibody systems in a highly endemic area. Am J Epidemiol. 1977;105(2):99-106. (Pubitemid 8042977)
10. Skinhøj P, McNair A, Andersen ST. Hepatitis and hepatitis B-antigen in Greenland. Am J Epidemiol. 1974;99(1):50-57.
11. Friborg J, Koch A, Wohlfahrt J, Storm HH, Melbye M. Cancer in Greenlandic Inuit 1973-1997: a cohort study. Int J Cancer. 2003;107(6):1017-1022. (Pubitemid 37429845)
12. Børresen ML, Olsen OR, Ladefoged K, et al. Hepatitis D outbreak among children in a hepatitis B hyperendemic settlement in Greenland. J Viral Hepat. 2010; 17(3):162-170.
13. Krause T, Koch A, Friborg J, Poulsen LK, Kristensen B, Melbye M. Frequency of atopy in the Arctic in 1987 and 1998. Lancet. 2002;360(9334):691- 692. (Pubitemid 35232340)
14. Krause TG, Koch A, Poulsen LK, Kristensen B, Olsen OR, Melbye M. Atopic sensitization among children in an arctic environment. Clin Exp Allergy. 2002;32(3): 367-372. (Pubitemid 34415635)
15. Banatvala J, Van DP, Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 2000;19(7-8): 877-885.
16. Hansen CH, Koch A, Wohlfahrt J, Melbye M. A population-based register study of vaccine coverage among children in Greenland. Vaccine. 2003;21(15): 1704-1709. (Pubitemid 36287600)
17. Krarup HB, Andersen S, Madsen PH, Okkels H, Hvingel BH, Laurberg P. Benign course of long-standing hepatitis B virus infection among Greenland Inuit? Scand J Gastroenterol. 2008;43(3):334-343. (Pubitemid 351238365)
18. Stevens CE, Toy PT, Taylor PE, Lee T, Yip HY. Prospects for control of hepatitis B virus infection: implications of childhood vaccination and long-term protection. Pediatrics. 1992;90(1 pt 2):170-173.
19. Mackie CO, Buxton JA, Tadwalkar S, Patrick DM. Hepatitis B immunization strategies: timing is everything. CMAJ. 2009;180(2):196-202.
20. Dentinger CM, McMahon BJ, Butler JC, et al. Persistence of antibody to hepatitis B and protection from disease among Alaska natives immunized at birth. Pediatr Infect Dis J. 2005;24(9):786-792. (Pubitemid 41324887)
21. Liang X, Bi S, Yang W, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis. 2009;200(1): 39-47.
22. Huang LM, Chiang BL, Lee CY, Lee PI, Chi WK, Chang MH. Long-term response to hepatitis B vaccination and response to booster in children born to mothers with hepatitis B e antigen. Hepatology. 1999;29(3): 954-959.
23. Zanetti AR, Van DP, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26(49):6266-6273.
24. McMahon BJ, Dentinger CM, Bruden D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390-1396.
25. Samandari T, Fiore AE, Negus S, et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics. 2007;120(2):e373-e381. (Pubitemid 47219488)
26. McMahon BJ, Bruden DL, Petersen KM, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142(5):333-341. (Pubitemid 40293406)
27. Banatvala J, Van Damme P, Van Hattum J; for the European Consensus Group on Hepatitis B Immunity. Boosters for hepatitis B. Lancet. 2000;356(9226): 337-338.
28. Van Damme P, Banatvala JE. Vaccine induced protection against hepatitis B. BMJ. 2003;326(7380): 105. (Pubitemid 36092302)
29. Zuckerman JN. Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol. 2006;78(2):169-177. (Pubitemid 43132560)
30. Roome AJ, Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA. 1993;270(24):2931-2934. (Pubitemid 24000798)
31. Zuckerman JN, Zuckerman AJ. Mutations of the surface protein of hepatitis B virus. Antiviral Res. 2003;60(2):75-78. (Pubitemid 37452449)
32. Sakamoto T, Tanaka Y, Simonetti J, et al. Classification of hepatitis B virus genotype B into 2 major types based on characterization of a novel subgenotype in Arctic indigenous populations. J Infect Dis. 2007; 196(10):1487-1492. (Pubitemid 351411985)
33. Nelson CM, Wibisono H, Purwanto H, Mansyur I, Moniaga V, Widjaya A. Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions. Bull World Health Organ. 2004;82(2):99-105. (Pubitemid 38282057)
34. Davaalkham D, Ojima T, Wiersma S, et al. Administration of hepatitis B vaccine in winter as a significant predictor of the poor effectiveness of vaccination in rural Mongolia: evidence from a nationwide survey. J Epidemiol Community Health. 2007;61(7):578-584. (Pubitemid 46998887)
35. Hatziandreu EJ, Hatzakis A, Hatziyannis S, Kane MA, Weinstein MC. Cost-effectiveness of hepatitis-B vaccine in Greece: a country of intermediate HBV endemicity. Int J Technol Assess Health Care. 1991; 7(3):256-262.